Related Experiment Videos
Control of phosphatidylcholine biosynthesis in myopathic hamster hearts
Insights
Myopathic hamster hearts show increased phosphatidylcholine labeling due to elevated CDP-choline specific radioactivity, despite unchanged total levels. This compensatory mechanism maintains biosynthesis despite reduced CTP levels.
Area of Science:
- Biochemistry
- Cardiovascular Biology
- Cellular Metabolism
Background:
- Phosphatidylcholine is crucial for cardiac membrane structure and function.
- The CDP-choline pathway is the primary route for phosphatidylcholine synthesis in the heart.
- Cardiac myopathy can alter cellular metabolic pathways, including lipid biosynthesis.
Purpose of the Study:
- To investigate phosphatidylcholine biosynthesis in myopathic hamster hearts.
- To compare phosphatidylcholine labeling and intermediate levels between myopathic and control hamster hearts.
- To elucidate the mechanisms behind altered phosphatidylcholine metabolism during cardiomyopathy.
Main Methods:
- Perfusion of hamster hearts with [Me-3H]choline.
- Quantification of phosphatidylcholine labeling and pool size.
- Analysis of CDP-choline labeling, pool size, and specific radioactivity.
- Measurement of CTP concentration and phosphocholine cytidylyltransferase activity.
Main Results:
- Myopathic hamster hearts showed a 22% increase in phosphatidylcholine labeling compared to controls.
- Total cardiac phosphatidylcholine levels remained unchanged in myopathic hearts.
- CDP-choline levels and labeling were reduced in myopathic hearts, but its specific radioactivity increased by 20%.
- CTP concentration decreased, while phosphocholine cytidylyltransferase activity increased in myopathic hearts.
Conclusions:
- The increased phosphatidylcholine labeling in myopathic hearts directly reflects the elevated specific radioactivity of CDP-choline.
- Reduced CTP concentration likely impairs CDP-choline formation, but increased phosphocholine cytidylyltransferase activity acts as a compensatory mechanism.
- These adaptations aim to maintain a minimum CDP-choline level and prevent a reduction in net phosphatidylcholine biosynthesis during cardiomyopathy.
Abstract:
A previous report from this laboratory demonstrated that the majority of phosphatidylcholine in hamster heart was formed from choline via the CDP-choline pathway (Zelinski, T. A., Savard, J. D., Man, R. Y. K., and Choy, P. C. (1980) J. Biol. Chem. 255, 11423-11428). In this study, phosphatidylcholine biosynthesis in myopathic hamster hearts was compared with date-matched controls. Upon perfusion with [Me-3H]choline, a 22% increase in labeling of phosphatidylcholine was observed in the hearts of 150-200-day-old myopathic hamsters. However, total cardiac phosphatidylcholine remained unchanged. In order to elucidate the cause for the increase in labeling of phosphatidylcholine during cardiomyopathy, the intermediates for phosphatidylcholine formation in the myopathic hearts were analyzed. The labeling and pool size of CDP-choline in the myopathic hearts were found to be 72 and 60% of the controls. This uneven reduction caused a 20% increase in the specific radioactivity of CDP-choline. Since CDP-choline is the immediate precursor for phosphatidylcholine formation, it can be concluded that the increase in labeling of phosphatidylcholine in the myopathic heart was a direct reflection on the specific radioactivity of CDP-choline. Furthermore, the net amount of phosphatidylcholine synthesized was estimated to be similar between the normal and myopathic hearts. The reduction in CDP-choline formation was probably caused by an observed decrease in CTP concentration in cardiomyopathy. However, phosphocholine cytidylyltransferase activity was elevated. The enhanced enzyme activity is regarded as one of the compensatory mechanism for the myopathic heart to maintain a minimum CDP-choline level, in order to prevent reduction of net phosphatidylcholine biosynthesis.